BOOK NOW TO SAVE
UP TO €500

10th-12th October | Frankfurt, Germany

www.NASH-Europe.com

NASH Summit EUROPE

Accelerate the Development of Your Nonalcoholic Steatohepatitis (NASH) Drug Pipeline

Focused on drug discovery to late stage clinical development, NASH Summit will tackle the challenges preventing high impact progress in the field

18 Expert Speakers:

Peter Traber
Chief Executive Officer & Chief Medical Officer
Galectin Therapeutics

Marie Wickström Lindholm
Expert Scientist
Roche Innovation Center Copenhagen

Tomas Landh
Innovation Sourcing Vice President & Senior Principal Scientist
Novo Nordisk

Sophie Megnien
Chief Medical Officer
Genfit

Philippe Weisel
Chief Medical Officer & Vice President
Genkyotex

> "As a newcomer to the NASH space, I found the meeting to be incredibly informative and intellectually stimulating. The meeting was well organized and very comprehensive"
>
> Inception Sciences, NASH Summit Boston Attendee

Spotlight Partner:
organovo

Tel: +44 203 141 8700 Email: info@hansonwade.com

Nonalcholic Steatohepatitis (NASH) Group

hansonwade
love what you do

Welcome to NASH Summit Europe

Enabling Drug Developers to Bring NASH Drugs to Market Faster

The **NASH Summit** is Europe's first **industry-led summit** which solves the challenges drug developers face **from target discovery through to late stage clinical development.**

Built with industry experts at **Genfit**, **Phenex** and **MedImmune** this comprehensive forum will help you **identify and validate novel targets, better recapitulate human NASH disease *in vivo*** and **robustly diagnose patient populations using non-invasive technologies.**

Join your peers at **NASH Summit** to learn from and engage with leading experts and **accelerate your NASH drug candidate development.**

Top 5 Reasons to Attend NASH Summit Europe

1. **Effectively translate into the clinic** by harnessing preclinical models which better recapitulate human NASH
2. Evaluate the most progressive opportunities in non-invasive diagnostics to **determine disease diagnosis and regression**
3. Define clinical primary and secondary endpoints and **successfully bring a NASH drug to market**
4. Improve understanding of core disease pathways to **identify and validate novel NASH targets**
5. Discover how NASH impacts other body organs to **develop more efficacious drugs**

Hear What Previous Attendees Have To Say:

"Thank you for a valuable meeting. It was great to follow up the current trends in NASH field and to know other researchers and developers"
NASH Summit Boston Attendee, **Takeda Pharmaceuticals**

"Best meeting for industries and valuable information. This meeting furthers my understanding of the current situation and future perspectives"
NASH Summit Boston Attendee, **Shionogi Co & Ltd**

"This is a good conference with the right timing as NASH becomes a focused disease area for many companies. I thought the speakers and participants represent the industry well"
NASH Summit Boston Attendee, **Celgene**

Tel: +44 203 141 8700 Email: info@hansonwade.com
www.NASH-Europe.com Nonalcholic Steatohepatitis (NASH) Group

18 Expert Speakers

Claus Kremoser
Chief Executive Officer
Phenex

Dean Hum
Chief Scientific Officer
Genfit

Pierre Broqua
Chief Scientific Officer & Co-Founder
Inventiva

Gerd Kullak-Ublick
Professor, Clinical Pharmacology
University Hospital of Zurich

Hans Schambye
Chief Executive Officer
Galecto Biotech

James Trevaskis
Principal Scientist & Head of In Vivo Pharmacology
MedImmune

Liat Hayardeny
Chief Scientific Officer
Galmed Pharmaceuticals

Marie Wickström Lindholm
Expert Scientist
Roche Innovation Center Copenhagen

Matthias Ocker
Head, Biomarker Oncology
Bayer

Peter Traber
Chief Executive Officer & Chief Medical Officer
Galectin Therapeutics

Philippe Weisel
Chief Medical Officer & Vice President
Genkyotex

Pnina Fishmann
Chief Executive Officer & Chief Scientific Officer
Can-Fite BioPharma

Sophie Megnien
Chief Medical Officer
Genfit

organovo

Speaker to be Confirmed

Tomas Landh
Innovation Sourcing Vice President & Senior Principal Scientist
Novo Nordisk

Weilin Xie
Senior Principal Scientist
Celgene

George O'Rourke
Managing Director
GO Biotech Consulting

Ronit Shiri-Sverdlov
Professor, Hepatic Inflammation and Metabolic Health
Maastricht University

"Outstanding meeting with first class speakers. I learned a lot and I will certainly recommend the meeting to my colleagues...."
Previous Hanson Wade Life Science Event Attendee, **Sanofi**

Conference Day One | Wednesday 11th October

Peter Traber, Chief Executive Officer & Chief Medical Officer, **Galectin Therapeutics**

8.45 **Chair's Opening Remarks**

Winning the Dash for NASH: Harnessing Recent Advances to Accelerate Drug Development

Sophie Megnien, Chief Medical Officer, **Genfit**

9.00 **Keynote: How is the Field Conquering this Global Health Crisis? Review Latest Advancements in NASH Drug Development**

- Comprehensively explore recent developments in NASH drug development
- Evaluate the regulatory feedback on the development of late stage clinical NASH candidates
- Discuss the current challenges and how we will progress as a field

9.30 **Speed Networking**

This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. Get face-to-face time with many of the brightest minds working in the NASH field and establish meaningful business relationships.

10.00 **Morning Refreshments**

Tomas Landh, Innovation Sourcing Vice President & Senior Principal Scientist, **Novo Nordisk**

Matthias Ocker, Head, Biomarker Oncology, **Bayer**

Liat Hayardeny, Chief Scientific Officer, **Galmed Pharmaceuticals**

10.30 **Key Opinion Leaders Discuss: Challenges & Opportunities in NASH Drug Development**

- Enhancing clinical trial design to improve patient enrolment
- Explore pioneering advances in non-invasive diagnostic technologies
- Harnessing the power of combinations – discuss the opportunity to combine anti-inflammatory and anti-fibrotic compounds

Identify & Validate Druggable & Clinically Relevant NASH Mechanisms

Marie Wickström Lindholm, Discovery Technology Expert Scientist, **Roche Innovation Center Copenhagen**

11.00 **Exploring Key Regulators in NASH**

- Enhance understanding of known and novel regulators in NASH
- Explore the design and testing of single stranded antisense molecules that target specific proteins, which could be a key regulator in NASH development
- Review the exploratory and pre-clinical development research

Philippe Weisel, Chief Medical Officer & Vice President, **Genkyotex**

11.30 **Targeting Multiple Fibrogenic Pathways with the NOX1/4 Inhibitor GKT831**

- Discover NADPH oxidases (NOX)
- Explore GKT831's mechanism of action - targeting multiple fibrogenic pathways
- Anti-fibrotic efficacy achieved in multiple preclinical models of liver disease (NASH, PBC)
- Gain a comprehensive understanding of clinical efficacy and safety profiles
- Overview of ongoing phase 2 trial in primary biliary cholangitis

12.00 **Lunch & Networking**

Hans Schambye, Chief Executive Officer, **Galecto Biotech**

1.00 **Analyse Recent Progress in Targeting NASH Fibrosis - Novel Inhibitors of Galectin-3**

- Advance your understanding of how galectin-3 plays central role in fibrosis process
- Examine how novel galectin-3 inhibitors reduce liver fibrosis

1.30 **Think Tank Roundtables**

More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas.

A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly, this is a dedicated opportunity for you to voice your experiences and identify unique solutions.

2.00 **Moderator Feedback & Audience Debate**

Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtables, they will present back to the entire delegation as part of a panel discussion to share ideas and best practice.

2.30 **Afternoon Refreshments & Networking**

Better Recapitulate Human NASH Preclinically & Effectively Translate into Clinical Development

Speaker to be Confirmed, Organovo

3.30 **Modelling Progressive Liver Disease Using 3D Bioprinted Human Liver Tissue**

- More details to follow

Claus Kremoser, Chief Executive Officer, **Phenex**

3.45 **Truthful In-Depth Review of the Advantages & Disadvantages of Preclinical Models**

- Overview of the wide range of rodent models currently used to model NAFLD/NASH, from diet to genetic & chemical models
- How should we be effectively evaluating NAFLD/NASH therapies from the plethora of rodent models available? Can we draw robust conclusions from an in-depth comparison of running animal models in parallel?
- Identify an industry standard model? If we agree, how do we get there?

Peter Traber, Chief Executive Officer & Chief Medical Officer, **Galectin Therapeutics**

4.15 **Chair's Closing Remarks**

4.30 **Scientific Poster Session**

After the formal presentations have finished, the learning and networking carries on. The Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session scientific posters will be presented on validation on novel targets, drugs with new mechanisms of action, in vivo models which recapitulate human NASH and latest progress in validating non-invasive diagnostic and prognostic technologies.

"Excellent conference with good presentations and wonderful networking opportunities"
Previous Hanson Wade Life Science Event Attendee, **ImmunoGen**

Conference Day Two | Thursday 12th October

Peter Traber, Chief Executive Officer & Chief Medical Officer, **Galectin Therapeutics**

9.15 **Chair's Opening Remarks**

Confidently Diagnose & Stratify NASH Patient Populations

Dean Hum, Chief Scientific Officer, **Genfit**

9.30 **Identification of Biomarkers for the Diagnosis of NASH**

- Explore novel biomarkers for a better diagnosis of NASH
- Discover new scores that enable the discrimination of NASH patients from NAFLD
- Review the development of a companion tool for Elafibranor

10.00 **Morning Refreshments & Networking**

Enhance NASH Compound Preclinical Development Strategy

James Trevaskis, Principal Scientist & Head of In Vivo Pharmacology, **MedImmune**

11.00 **Prosecuting Metabolic Modulators as NASH Therapeutics**

- Discuss current standard rodent models that reflect different disease pathologies
- Robustly interpret pathology in mouse models and the benefit of a biopsy
- Translate the effect of NASH therapeutics from mice to man

Weilin Xie, Senior Principal Scientist, **Celgene**

11.30 **Targeting NASH Fibrosis Through Modulating Wnt Signaling Pathway**

- Improve understanding of the challenges involved with developing a comprehensive NASH candidate development strategy
- Explore the discovery and preclinical development of a novel NASH targeting candidates
- Review preclinical data and understand how this suggests further development of novel compound

12.00 **Lunch & Networking**

Explore Developments in Clinical Trial Design for Improved Patient Enrolment

Pnina Fishman, Chief Executive Officer & Chief Scientific Officer, **Can-Fite BioPharma**

1.00 **The Anti-Fibrogenic and Liver Protective Effects of Namodenoson (CF102): From Preclinical to Human Studies**

- Discover Namodenoson (CF102), an A3 adenosine receptor (A3AR) agonist known to induce anti-inflammatory and protective effects in the liver
- Explore CF102 mechanism of action via down regulation of the Wnt and the NF-kB signal transduction pathways, resulting in apoptosis of pathological cells
- Review the development of CF102 in Phase II clinical studies

Pierre Broqua
Chief Scientific Officer
Inventiva

1.30 **IVA337: Effectively Targeting NASH**

- IVA337 is a new chemical entity that activates the three PPAR (peroxisome proliferator-activated receptor) isoforms: Đ, Đ and Đ
- Evaluate the in vitro and in vivo preclinical development of IVA337, where IVA337 induced the regression of pre-existing fibrotic damage in the liver and prevented further fibrosis from developing
- Examine the latest clinical data which demonstrates efficacy of IVA337

2.00 **Afternoon Refreshments & Networking**

Looking Towards 2018: Advance Understanding of How the Field will Evolve

Gerd Kullak-Ublick, Professor, Clinical Pharmacology, **University Hospital of Zurich**

3.00 **Determine Protective Effects of FXR Agonists on Kidney Function in Obesity**

- Learn that obesity is not only a risk factor for NASH, but also an independent risk factor for chronic kidney disease, leading to glomerulosclerosis and renal insufficiency
- Gain an in-depth understanding of how renal lipid accumulation and lipotoxicity play an important role in the pathogenesis of renal injury
- Review the development of ligands of the farnesoid X receptor (FXR), which attenuate kidney damage induced by obesity by reducing renal lipid accumulation and activating protective signalling pathways
- Discuss how the protective effect of FXR ligands on kidney function opens up new indications for this class of therapeutic ligands, for instance in the context of kidney donation by obese donors

Selection of Leading NASH Experts

3.30 **Panel Discussion: What Does the Next 12 Months Hold for NASH Therapeutic Development?**

- Lessons learned from progress in the field during 2017
- What still needs to be done? How are we going to over come the main challenges?
- Speculation on developments for the next 12 months

Peter Traber, Chief Executive Officer & Chief Medical Officer, **Galectin Therapeutics**

4.00 **Chair's Closing Remarks**

Pre-Conference Workshops | Tuesday 10th October

WORKSHOP A

Effectively Build Entry Strategies into the European NASH Market

10.00am – 1.00pm

With a continually growing patient population and no approved treatments, NASH presents a huge unmet clinical need. Drug developers are racing to bring an effective therapeutic to market as quickly as possible. However, developing a robust market entry strategy for Europe is not without its challenges.

Join your peers and industry leading experts at this workshop to learn how to navigate the European drug development landscape.

Attend this expert led workshop to:

- Gain a comprehensive understanding of the drivers of NASH disease and challenges ahead in bringing a drug to market in the European landscape.
- Quantify the enormity of the clinical and economic burdens of NAFLD/NASH, which will likely increase as the incidence of NAFLD continues to rise.
- Predict what the next 12 months hold for NASH drug development in Europe.

Workshop Leader

George O'Rourke

Managing Director

GO Biotech Consulting

WORKSHOP B

Improving Understanding of Molecular Mechanisms that are Driving NASH & Robustly Testing Your Hypothesis Preclinically

2.00pm – 5.00pm

The molecular mechanisms triggering NASH in the liver are unknown. Currently, there is a lack of industry consensus on the mechanisms driving NASH disease and therefore which are the most appropriate to target therapeutically.

Furthermore, replicating human NASH disease in vivo is one of the most challenging aspects of preclinical drug development.

Currently there are a plethora of animal models available, however, no mice model completely fulfils the clinical features observed in humans.

This workshop will review the latest advances in understanding the molecular mechanisms driving NASH disease. We will review commonly used animal models of NAFLD/NASH referring to their advantages and disadvantages. You will leave this workshop with a comprehensive understanding of potential mechanisms driving NASH and which mouse models are most appropriate for your NASH candidate.

Join this workshop to:

- Discuss the mechanisms by which inflammation is triggered.
- Objectively review the plethora of animal models available for NASH and highlight their advantages and disadvantages.
- Learn how to comprehensively test your NASH drugs mode of action in the most appropriate models for that drug.

Workshop Leader

Ronit Shiri-Sverdlov

Professor, Hepatic Inflammation and Metabolic Health

Maastricht University

Partnership Opportunities

Your brand, your message, your reputation showcased in front of the leading minds of NASH drug development.

Partnering with this summit is your opportunity to **elevate your company's standing in the NASH industry**.

Whether you're on the brink of **validating your approach and need to communicate this exciting progress** or you're simply looking to **generate leads**, put **names to faces** or **get a grasp of this fast-paced market**, you can rely on our ability to advise on, and deliver, the right solution for you.

To learn more about how we can support your efforts get in touch today at sponsor@hansonwade.com

SENIORITY OF ATTENDEES*



- C—Level **11%**
- President/Vice President **17%**
- Global Head/Head of **33%**
- Director/Associate Director **21%**
- Scientist **15%**
- Professor **3%**

TYPES OF COMPANIES ATTENDING*



- Pharma
- Biotech
- Equipment & Service Providers
- Research Institute
- Consultant

SPOTLIGHT PARTNER

organovo

Organovo develops dynamic, multi-cellular, and fully-human tissues that closely model native architecture and biology. With the NovoGen Brioprinter® Platform, the Company designs tissues for use in applications spanning preclinical safety testing, disease modeling, and regenerative medicine. Tissues are commercially available through its NovoView™ Service Offering and through strategic partnerships. Organovo's bioprinted tissues enable mechanistic insights into phenotypes that progress over time and that require multiple cell types in a specific spatial organization, reflecting the true complexity of human biology.

WHO'LL ATTEND THE NASH SUMMIT?

abbvie · Allergan · AMGEN · AstraZeneca · Bayer · Boehringer Ingelheim · Bristol-Myers Squibb · Celgene · Daiichi-Sankyo · Eisai · ENANTA Pharmaceuticals · Lilly · Genentech A Member of the Roche Group · GENFIT Towards Better Medicine · gsk · Intercept · Johnson & Johnson · MedImmune · MERCK · NOVARTIS · Pfizer · Roche · SANOFI · Shire · Takeda

"First class meeting – incredible opportunity to meet directly with a broad range of decision makers in this growing field"
Quanta Biodesign – previous Hanson Wade Life Science Event Sponsor

Contact us today to find out how we can help you achieve your business goals faster.

Jakub Nunuk
Partnership Manager
Tel: +44 203 141 8700
Email: sponsor@hansonwade.com

Ready to Register?

3 EASY WAYS TO BOOK

nash-europe.com/attend/register

Tel: +44 203 141 8700

Email: register@hansonwade.com

TOP 3 BENEFITS OF ATTENDING

1. **Effectively translate into the clinic** using preclinical models which better recapitulate human NASH
2. Evaluate the most progressive opportunities in biomarkers and non-invasive technologies to **determine disease diagnosis and regression**
3. Define clinical primary and secondary endpoints and **successfully bring a NASH drug to market**

Team Discounts*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

* Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

SECURE YOUR PLACE

Package Details	Register & Pay before 7th July	Register & Pay before 4th August	Register & Pay before 1st September	Standard Prices
Gold: Conference + 2 workshops	€3197+ VAT **(save €500)**	€3297 + VAT **(save €400)**	€3397 + VAT **(save €300)**	€3497 + VAT **(save €200)**
Silver: Conference + 1 workshop	€2698 +VAT **(save €400)**	€2798 + VAT **(save €300)**	€2898 + VAT **(save €200)**	€2998 + VAT **(save €100)**
Bronze: Conference only	€2199+ VAT **(save €300)**	€2299 + VAT **(save €200)**	€2399 + VAT **(save €100)**	€2499 + VAT

*Academics are entitled to a 40% discount off the Industry Pricing using the code 'ACA'
(Please note: Discounts cannot be combined with any other offer)

"Well organized conference with the opportunity to network with leaders in industry and drug development"

Previous Hanson Wade Life Science Event Attendee, Virginia Commonwealth University

"Conference organisers from Hanson Wade were excellent and very professional"

Previous Hanson Wade Life Science Event Attendee, Ardelyx Inc







VENUE

The Westin Grand Frankfurt
Konrad Adenauer Strasse 7, Frankfurt, 60313, Germany

For further information or assistance, please visit www.westingrandfrankfurt.com/en

Code: 0000